ATE440860T1 - An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen - Google Patents

An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen

Info

Publication number
ATE440860T1
ATE440860T1 AT02774847T AT02774847T ATE440860T1 AT E440860 T1 ATE440860 T1 AT E440860T1 AT 02774847 T AT02774847 T AT 02774847T AT 02774847 T AT02774847 T AT 02774847T AT E440860 T1 ATE440860 T1 AT E440860T1
Authority
AT
Austria
Prior art keywords
protein phosphatase
synthetic
applications
identification methods
peptides
Prior art date
Application number
AT02774847T
Other languages
English (en)
Inventor
Alphonse Garcia
Xavier Cayla
Angelita Rebollo
Gordon Langsley
Original Assignee
Pasteur Institut
Agronomique Inst Nat Rech
Consejo Superior Investigacion
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Agronomique Inst Nat Rech, Consejo Superior Investigacion, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE440860T1 publication Critical patent/ATE440860T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT02774847T 2001-07-27 2002-07-26 An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen ATE440860T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0110139A FR2827866B1 (fr) 2001-07-27 2001-07-27 Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
PCT/FR2002/002705 WO2003011898A2 (fr) 2001-07-27 2002-07-26 Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations

Publications (1)

Publication Number Publication Date
ATE440860T1 true ATE440860T1 (de) 2009-09-15

Family

ID=8866042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774847T ATE440860T1 (de) 2001-07-27 2002-07-26 An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen

Country Status (11)

Country Link
US (2) US20060014930A1 (de)
EP (1) EP1530584B1 (de)
JP (2) JP4439261B2 (de)
KR (2) KR20090060462A (de)
CN (1) CN1630663B (de)
AT (1) ATE440860T1 (de)
CA (1) CA2455403C (de)
DE (1) DE60233532D1 (de)
ES (1) ES2331730T3 (de)
FR (1) FR2827866B1 (de)
WO (1) WO2003011898A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827866B1 (fr) * 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2003078448A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
FR2850396B1 (fr) * 2003-01-29 2005-05-13 Pasteur Institut Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
WO2004011595A2 (fr) * 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
CA2408207A1 (fr) * 2002-10-16 2004-04-16 Institut Pasteur Peptides liant la proteine phosphatase 2a et polynucleotides les codant
EP1682573B1 (de) * 2003-09-15 2014-01-01 Cenix Bioscience GmbH Verwendung von die zellzyklussteuerung oder die zellzyklusprogression beeinflussenden eukaryontischen genen zur diagnose und behandlung von proliferativen krankheiten
WO2005103654A2 (fr) * 2004-04-09 2005-11-03 Bioalliance Pharma Methode d’identification de composes actifs sur la replication du virus hiv.
WO2006084033A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2007022534A1 (en) * 2005-08-19 2007-02-22 Propepgen Biostrategies, Inc. Preparation of a peptide compound (norapro-2002) and its use for the activation of protein phosphatase-2a enzymes
FR2903305B1 (fr) * 2006-07-07 2012-06-01 Soc Extraction Principes Actif Utilisation d'extraits vegetaux en tant que principes actifs amincissants
EP2236603A1 (de) * 2009-03-30 2010-10-06 Universite Pierre Et Marie Curie Proapoptotische Peptide
EP2301956A1 (de) 2009-09-25 2011-03-30 Institut Pasteur Verfahren zum Prognostizieren des Fortschreitens oder langfristigen Nicht-Fortschreitens einer HIV-Infektion oder von HIV-assoziierten Erkrankungen in einem Patienten
EP2621944A2 (de) 2010-09-30 2013-08-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimäres peptid mit einem penetrierenden peptid und einer bindungsdomäne der pp2a-katalytischen untereinheit an caspase-9
JP6169607B2 (ja) * 2011-12-27 2017-07-26 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） 抗腫瘍アジュバント療法
WO2013098337A1 (en) * 2011-12-27 2013-07-04 Universite Pierre Et Marie Curie (Paris 6) Cell-penetrating peptides
CN103788211B (zh) * 2012-11-01 2017-09-01 中国科学院上海药物研究所 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物
EP2868326A1 (de) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptidhemmer der TEAD/YAP-TAZ-Interaktion
EP2881472A1 (de) 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) Verfahren zur Vorhersage einer Reaktion auf eine Antitumorbehandlung
US10688153B2 (en) 2015-11-06 2020-06-23 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
EP3658581A1 (de) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper und peptide zur behandlung von erkrankungen im zusammenhang mit hcmv
CN118146308A (zh) * 2020-04-30 2024-06-07 中国科学院分子细胞科学卓越创新中心 用于治疗胃癌的环肽及其药物组合物
US20250163116A1 (en) 2022-03-16 2025-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat infectious diseases
CN117187070A (zh) * 2022-12-07 2023-12-08 兰州大学 弓形虫弱毒株PruΔpp2a-a的构建方法和应用
CN117720655A (zh) * 2023-11-23 2024-03-19 南方医科大学 抗弓形虫的单克隆抗体及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087486A (en) * 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
WO1997037037A1 (en) * 1996-03-29 1997-10-09 Novartis Ag Phosphatase modulator
DE69725882T2 (de) * 1996-07-05 2004-07-29 Branton, Philip E., St. Lambert Adenovirus e4 proteine für induktion von zelltod
WO2001004629A1 (en) * 1999-07-12 2001-01-18 Mcgill University E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death
GB9925853D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US6664040B2 (en) * 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
CA2421872A1 (en) * 2000-09-11 2002-03-14 Institut Pasteur Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
FR2827866B1 (fr) * 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations

Also Published As

Publication number Publication date
FR2827866A1 (fr) 2003-01-31
JP2005522185A (ja) 2005-07-28
KR100950520B1 (ko) 2010-03-30
US20060014930A1 (en) 2006-01-19
KR20040044435A (ko) 2004-05-28
FR2827866B1 (fr) 2004-12-10
WO2003011898A2 (fr) 2003-02-13
CN1630663A (zh) 2005-06-22
CA2455403A1 (fr) 2003-02-13
ES2331730T3 (es) 2010-01-14
JP2009112309A (ja) 2009-05-28
US20110269674A1 (en) 2011-11-03
KR20090060462A (ko) 2009-06-12
EP1530584B1 (de) 2009-08-26
EP1530584A2 (de) 2005-05-18
US8299213B2 (en) 2012-10-30
WO2003011898A3 (fr) 2005-03-17
CA2455403C (fr) 2012-05-29
CN1630663B (zh) 2010-05-12
JP4439261B2 (ja) 2010-03-24
DE60233532D1 (de) 2009-10-08

Similar Documents

Publication Publication Date Title
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE382055T1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE496063T1 (de) Hybrid und tandemproteine von neisseria sp
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
ATE486087T1 (de) Fgf-5-bindende und geträgerte peptide
EP1696027A4 (de) Aus wt 1 stammendes, hla-dr bindendes antigenpeptid
ATE353914T1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
ATE429448T1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
DE60335726D1 (de) Chromoprotein und fluoroproteine
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
ATE447612T1 (de) Fluoreszenzproteine
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2002021138A3 (de) Die m30-genfamilie und ihre verwendung
WO2004035611A8 (fr) Peptides liant la proteine phosphatase 2a et polynucleotides les codant
WO2007030771A3 (en) Targeted identification of immunogenic peptides
DK2186898T3 (da) Blomstrings-induktion
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties